FULLER H B CO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On September 23, 2026, Ruth S. Kimmelshue notified H.B. Fuller Company (the “Company”) of her resignation as a member of the Board of Directors (“Board”) of the Company, effective immediately. Ms. Kimmelshue’s retirement as a director of the Company is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Ms. Kimmelshue for her dedication, commitment, and extraordinary service and wishes her continued success in all her future endeavors. (d) On September 23, 2026, the Board elected R. Jeffrey Bailly, age 64, as a Class I director of the Company, effective September 23, 2026, for an initial term expiring at the Company’s 2027 annual meeting of shareholders. Mr. Bailly also has been appointed to serve on the Audit Committee and the Compensation Committee of the Board. Since June 2026, Mr. Bailly has served as the Executive Chairman of the Board of UFP Technologies, Inc. (“UFP Technologies”), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. Prior to being named Executive Chairman of the Board, he served as Chief Executive Officer of UFP Technologies since 1995 and as its Chairman of the Board since 2006. Mr. Bailly brings more than three decades of executive leadership experience spanning business transformation, M&A, manufacturing, and medical technology. As CEO of UFP Technologies from 1995 to 2026, he led the transformation of the company into a leading global contract development and manufacturing organization focused on higher growth, higher margin medical end markets. During this time, the company expanded through more than 20 acquisitions and the addition of new capabilities, technologies, and markets, including its transformative 2018 acquisition of Dielectrics, which accelerated the company’s growth in medical technology. Mr. Bailly joined UFP Technologies in 1988 and served as a Division Manager from 1989 to 1992, General Manager Northeast Operations from 1992 to 1994, Vice President of Operations from 1994 to 1995, and as its President from 1995 to 2024. From 1984 through 1988, Mr. Bailly, a certified public accountant, was employed by Coopers & Lybrand. Mr. Bailly is a member of World Presidents’ Organization and holds a BA from Johns Hopkins University and an MBA from New York University. For service as a director of the Company, Mr. Bailly will receive an annual cash retainer of $100,000 and will also receive an initial grant of 1,300 restricted stock units of the Company. Directors are also eligible for an annual discretionary grant of deferred phantom stock units valued at $165,000. There are no arrangements or understandings between Mr. Bailly and any other persons pursuant to which Mr. Bailly was selected as a director of the Company. There are no transactions between Mr. Bailly and the Company that would be reportable under Item 404(a) of Regulation S-K. A copy of the press release announcing Mr. Bailly’s election to the Board is filed as Exhibit 99.1 hereto.